Zobrazeno 1 - 10 of 39 pro vyhledávání: '"Reiko E. Yamada"'
1
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
Autor: Jack Pengfei Tang, Cole W. Peters, Crystal Quiros, Xiaoyan Wang, Alexandra M. Klomhaus, Reiko E. Yamada, John M. Timmerman, Theodore B. Moore, Theodore S. Nowicki
Publikováno v: Cancer immunology research, vol 10, iss 12
Cancer Immunol Res
A major complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell–associated neurotoxicity syndrome (ICANS), which presents as aphasia, confusion, weakness, somnolence, seizures, and coma. This is similar to the neurolo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0f8f770d6b22bd92fe70d4e1f67a66
https://doi.org/10.1158/2326-6066.cir-22-0418
Zobrazit plný text záznamu
2
Data from Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
Autor: Theodore S. Nowicki, Theodore B. Moore, John M. Timmerman, Reiko E. Yamada, Alexandra M. Klomhaus, Xiaoyan Wang, Crystal Quiros, Cole W. Peters, Jack Pengfei Tang
A major complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell–associated neurotoxicity syndrome (ICANS), which presents as aphasia, confusion, weakness, somnolence, seizures, and coma. This is similar to the neurolo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28435b9d50fb3fc83c5654bc12e969c3
https://doi.org/10.1158/2326-6066.c.6550821.v1
Zobrazit plný text záznamu
3
Data from 89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model
Autor: Anna M. Wu, Sherie L. Morrison, John M. Timmerman, Alex Vasuthasawat, K. Ryan Trinh, Reiko E. Yamada, Felix B. Salazar, Kirstin A. Zettlitz
Antibody-mediated tumor delivery of cytokines can overcome limitations of systemic administration (toxicity, short half-lives). Previous work showed improved antitumor potency of anti-CD20-IFNα fusion proteins in preclinical mouse models of B-cell l
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac59594e3b84a8978cf8f66ac4461bc
https://doi.org/10.1158/1535-7163.c.6543252.v1
Zobrazit plný text záznamu
6
Data from Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
Autor: John M. Timmerman, David J. Betting, Geraldine S. Pinkus, Jonathan Said, Reiko E. Yamada, David J. Andorsky
Purpose: Programmed death ligand 1 (PD-L1) is expressed on antigen-presenting cells and inhibits activation of T cells through its receptor PD-1. PD-L1 is aberrantly expressed on some epithelial malignancies and Hodgkin lymphomas and may prevent effe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3315baa9dc5866a098cbdaa9dcd65d0
https://doi.org/10.1158/1078-0432.c.6519207
Zobrazit plný text záznamu
10
Data from A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
Autor: John M. Pagel, Naomi Hunder, Natarajan Muthusamy, Janet Kramer, Reiko E. Yamada, David J. Andorsky, John C. Byrd, John M. Timmerman
Purpose: We conducted a phase I study to determine the safety, maximum-tolerated dose (MTD), and efficacy of weekly bolus recombinant human interleukin-21 (rIL-21) plus rituximab in patients with indolent B-cell malignancies.Experimental Design: One
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38bf861669e9b2458055884b107c1233
https://doi.org/10.1158/1078-0432.c.6520809
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje